Taylor W A, Hughes R A
Neurology Department, United Medical, School of Guy's Hospital, London, U.K.
J Neuroimmunol. 1989 Sep;24(1-2):33-9. doi: 10.1016/0165-5728(89)90095-7.
Activated circulating T lymphocytes were measured in ten patients with Guillain-Barré syndrome (GBS) and in ten with chronic idiopathic demyelinating polyradiculoneuropathy (CIDP), each paired with an age- and sex-matched healthy control. Activated T cells were identified by double labelling with phycoerythrin-conjugated anti-CD3 antibody and biotinylated antibodies to activation antigens: human leucocyte antigen (HLA)-DR, transferrin receptor (TFR) or interleukin-2 receptor (IL-2R) visualised with an avidin-biotin-fluorescein system. The frequency of activated T cells was increased in the GBS group. The median of the DR-positive T cells in the patients was 3.4% (range 0.5-9.4%), compared with 1.4% (range 0-4.3%) in the controls (P less than 0.01). For TFR the corresponding medians were 3.3% (range 0.5-6.2%) in the patients and 0% (range 0-2.5%) in the controls (P less than 0.01), and for IL-2R 3.7% (range 0-6.0%) in the patients compared with 0% (range 0-2.9%) in the controls (P less than 0.01). In the CIDP group the median percentage of activated T cells was also increased but the differences were less significant: for DR, patients 2.4% (range 0-3.8%), controls 0.5% (range 0-2.0%, P less than 0.05); for TFR, patients 0% (range 0-5.3%), controls 0% (range 0-1.0%, not significant), and for IL-2R, patients 0% (range 0-2.5%), controls 0% (range 0-0.5%, not significant). The activated cells might be directed against microbial antigens encountered during the infection preceding GBS, autoantigens, bacterial antigens encountered during concurrent infection, or a combination of these.
对10例吉兰 - 巴雷综合征（GBS）患者和10例慢性特发性脱髓鞘性多发性神经根神经病（CIDP）患者进行了活化循环T淋巴细胞检测，每组均配对一名年龄和性别匹配的健康对照。通过用藻红蛋白偶联的抗CD3抗体和生物素化的活化抗原抗体进行双重标记来鉴定活化的T细胞：人白细胞抗原（HLA）-DR、转铁蛋白受体（TFR）或白细胞介素-2受体（IL-2R），使用抗生物素蛋白-生物素-荧光素系统进行可视化。GBS组中活化T细胞的频率增加。患者中DR阳性T细胞的中位数为3.4%（范围0.5 - 9.4%），而对照组为1.4%（范围0 - 4.3%）（P小于0.01）。对于TFR，患者和对照组的相应中位数分别为3.3%（范围0.5 - 6.2%）和0%（范围0 - 2.5%）（P小于0.01），对于IL-2R，患者为3.7%（范围0 - 6.0%），对照组为0%（范围0 - 2.9%）（P小于0.01）。在CIDP组中，活化T细胞的中位数百分比也有所增加，但差异不太显著：对于DR，患者为2.4%（范围0 - 3.8%），对照组为0.5%（范围0 - 2.0%，P小于0.05）；对于TFR，患者为0%（范围0 - 5.3%），对照组为0%（范围0 - 1.0%，无显著性差异），对于IL-2R，患者为0%（范围0 - 2.5%），对照组为0%（范围0 - 0.5%，无显著性差异）。活化细胞可能针对GBS发病前感染期间遇到的微生物抗原、自身抗原、并发感染期间遇到的细菌抗原或这些抗原的组合。
